Hongjun Gao

机构：Academy of Military Medical Sciences · ORCID：0000-0001-5277-4292

发表论文 103 篇 · 总被引 2120 次 · h-index 25

代表论文

• Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial (2023 · Journal of Thoracic Oncology · 被引 72)
• Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407 (2021 · JTO Clinical and Research Reports · 被引 52)
• Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study (2022 · Journal of Thoracic Oncology · 被引 29)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross‐sectional study (2022 · Thoracic Cancer · 被引 14)
• Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study (2021 · EClinicalMedicine · 被引 14)